Ruhuşen KUTLU, Fatma Gökşin CİHAN, Havva DEMİRCİOĞLU, Adil ZAMANİ, Şebnem YOSUNKAYA

Frequency of sarcopenia and associated outcomes in patients with chronic obstructive pulmonary disease

Background/aim: We aimed to evaluate the prevalence of sarcopenia and associated outcomes in patients with chronic obstructive pulmonary disease (COPD). Materials and methods: This cross-sectional study was performed on 219 patients aged 50 years and over who were diagnosed with chronic obstructive pulmonary disease (COPD) according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. The study included 196 (89.5%) male and 23 (10.5%) female patients. The mean age of the patients was 66.9 ± 10.1 years. To diagnose sarcopenia, muscle function was determined by a gait speed test. Muscle strength was assessed with a hand dynamometer and muscle mass was measured with a bioelectrical impedance analysis device. Pulmonary function tests and six-min walking tests were also performed. The modified Medical Research Council (mMRC) dyspnoea scale was used to evaluate all the participants. Our sample consisted of sarcopenic patients at different stages (17 presarcopenic patients (7.8%), 32 patients with sarcopenia (14.6%), 65 patients with severe sarcopenia (29.7%), and 105 nonsarcopenic patients (47.9%). Results: Sarcopenia was significantly associated with age, BODE (body mass index (BMI), airflow obstruction, dyspnoea, and exercise capacity) index, GOLD spirometric classification, mMRC dyspnoea scale score, BMI, and educational status. Sarcopenia in COPD patients was firmly related to the severity of the disease and its prognosis. The prevalence of sarcopenia increased in severe and very severe COPD cases. The dyspnoea score was higher, and exercise capacities were lower in sarcopenic patients. Conclusions: Sarcopenia in COPD patients was closely related to the severity of COPD and a negative prognosis. The frequency of sarcopenia increased in severe and very severe COPD cases. Dyspnoea scores were higher and exercise capacities were lower in patients with sarcopenia. In patients with COPD, a diagnosis of sarcopenia should be considered, and preventive measures should be taken before irreversible changes develop.

PDF

___

1. Rolland Y, Czerwinski S, Abellan Van Kan G, Morley JE, Cesari M et al. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. The Journal of Nutrition, Health and Aging 2008; 12 (7): 433-450.
2. Greenlund LJ, Nair KS. Sarcopenia--consequences, mechanisms, and potential therapies. Mechanisms of Ageing and Development 2003; 124 (3): 287-299.
3. Hogg J. Peripheral lung remodelling in asthma and chronic obstructive pulmonary disease. European Respiratory Journal 2004; 24 (6): 893-894. doi: 10.1183/09031936.04.00110704
4. Swallow EB, Reyes D, Hopkinson NS, Man WD, Porcher R et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax 2007; 62 (2): 115-120. doi: 10.1136/thx.2006.062026
5. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V et al. Standardisation of the measurement of lung volumes. European Respiratory Journal 2005; 26 (3): 511-522. doi: 10.1183/09031936.05.00035005
6. Bahat G, Tufan A, Kilic C, Karan MA, Cruz-Jentoft AJ. Methodological issues in determination of low muscle mass reference cut-off values: reply to comment on “cut-off points to identify sarcopenia according to European Working Group on Sarcopenia in Older People (EWGSOP) definition”. Clinical Nutrition 2017; 36 (3): 903-904. doi: 10.1016/j.clnu.2017.02.023
7. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age and Ageing 2010; 39 (4): 412- 423. doi: 10.1093/ageing/afq034
8. Bahat G, Tufan A, Tufan F, Kilic C, Akpinar TS et al. Cut-off points to identify sarcopenia according to European Working Group on Sarcopenia in Older People (EWGSOP) definition. Clinical Nutrition 2016; 35 (6): 1557-1563. doi: 10.1016/j. clnu.2016.02.002
9. Costa TM, Costa FM, Moreira CA, Rabelo LM, Boguszewski CL et al. Sarcopenia in COPD: relationship with COPD severity and prognosis. The Jornal Brasileiro de Pneumologia 2015; 41 (5): 415-421. doi: 10.1590/S1806-37132015000000040
10. Limpawattana P, Inthasuwan P, Putraveephong S, Boonsawat W, Theerakulpisut D et al. Sarcopenia in chronic obstructive pulmonary disease: a study of prevalence and associated factors in the Southeast Asian population. Chronic Respiratory Disease 2018; 15 (3): 250-257. doi: 10.1177/1479972317743759
11. Morley JE. Sarcopenia: diagnosis and treatment. The Journal of Nutrition Health and Aging 2008; 12 (7): 452-456.
12. Abellan Van Kan G. Epidemiology and consequences of sarcopenia. The Journal of Nutrition, Health and Aging 2009; 13 (8): 708-712.
13. Akin S, Mucuk S, Ozturk A, Mazicioglu M, Gocer S et al. Muscle function-dependent sarcopenia and cut-off values of possible predictors in community-dwelling Turkish elderly: calf circumference, midarm muscle circumference and walking speed. European Journal of Clinical Nutrition 2015; 69 (10): 1087-1090. doi: 10.1038/ejcn.2015.42
14. Bahat G, Saka B, Tufan F, Akin S, Sivrikaya S et al. Prevalence of sarcopenia and its association with functional and nutritional status among male residents in a nursing home in Turkey. The Aging Male 2010; 13 (3): 211-214. doi: 10.3109/13685538.2010.489130
15. Munhoz Da Rocha Lemos Costa T, Costa FM, Jonasson TH, Moreira CA, Boguszewski CL et al. Body composition and sarcopenia in patients with chronic obstructive pulmonary disease. Endocrine 2018; 60 (1): 95-102. doi: 10.1007/s12020- 018-1533-4
16. Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. The American Journal of Clinical Nutrition 2005; 82 (1): 53-59. doi: 10.1093/ajcn.82.1.53
17. Jones SE, Maddocks M, Kon SS, Canavan JL, Nolan CM et al. Sarcopenia in COPD: prevalence, clinical correlates and response to pulmonary rehabilitation. Thorax 2015; 70 (3): 213-218. doi: 10.1136/thoraxjnl-2014-206440
18. De Blasio F, Di Gregorio A, De Blasio F, Bianco A, Bellofiore B et al. Malnutrition and sarcopenia assessment in patients with chronic obstructive pulmonary disease according to international diagnostic criteria, and evaluation of raw BIA variables. Respiratory Medicine 2018; 134: 1-5. doi: 10.1016/j. rmed.2017.11.006
19. Ischaki E, Papatheodorou G, Gaki E, Papa I, Koulouris N et al. Body mass and fat-free mass indices in COPD: relation with variables expressing disease severity. Chest 2007; 132 (1): 164- 169. doi: 10.1378/chest.06-2789
20. Ries AL, Bauldoff GS, Carlin BW, Casaburi R, Emery CF et al. Pulmonary rehabilitation: joint ACCP/AACVPR evidencebased clinical practice guidelines. Chest 2007; 131 (5 Suppl): 4S-42S. doi: 10.1378/chest.06-2418
21. Byun MK, Cho EN, Chang J, Ahn CM, Kim HJ. Sarcopenia correlates with systemic inflammation in COPD. International Journal of Chronic Obstructive Pulmonary Disease 2017; 12: 669-675. doi: 10.2147/COPD.S130790
22. Leem AY, Park B, Kim YS, Jung JY, Won S. Incidence and risk of chronic obstructive pulmonary disease in a Korean community-based cohort. International Journal of Chronic Obstructive Pulmonary Disease 2018; 13: 509-517. doi: 10.2147/COPD.S148618
23. Lainscak M, Von Haehling S, Doehner W, Sarc I, Jeric T et al. Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. Journal of Cachexia, Sarcopenia and Muscle 2011; 2 (2): 81-86. doi: 10.1007/s13539-011-0023-9
24. Pothirat C, Chaiwong W, Phetsuk N, Liwsrisakun C, Bumroongkit C et al. The relationship between body composition and clinical parameters in chronic obstructive pulmonary disease. Journal of the Medical Association of Thailand 2016; 99 (4): 386-393.
25. Wagner PD. Possible mechanisms underlying the development of cachexia in COPD. European Respiratory Journal 2008; 31 (3): 492-501. doi: 10.1183/09031936.00074807
26. Ryu M, Jo J, Lee Y, Chung YS, Kim KM et al. Association of physical activity with sarcopenia and sarcopenic obesity in community-dwelling older adults: the Fourth Korea National Health and Nutrition Examination Survey. Age and Ageing 2013; 42 (6): 734-740. doi: 10.1093/ageing/aft063
27. Burtin C, Ter Riet G, Puhan MA, Waschki B, Garcia-Aymerich J et al. Handgrip weakness and mortality risk in COPD: a multicentre analysis. Thorax 2016; 71 (1): 86-87. doi: 10.1136/ thoraxjnl-2015-207451
28. Kim TN, Choi KM. Sarcopenia: definition, epidemiology, and pathophysiology. Journal of Bone Metabolism 2013; 20 (1): 1-10. doi: 10.11005/jbm.2013.20.1.1
29. Auyeung TW, Lee SW, Leung J, Kwok T, Woo J. Age-associated decline of muscle mass, grip strength and gait speed: a 4-year longitudinal study of 3018 community-dwelling older Chinese. Geriatrics and Gerontology International 2014; 14 (Suppl 1): 76- 84. doi: 10.1111/ggi.12213
30. Slinde F, Gronberg A, Engstrom CP, Rossander-Hulthen L, arsson S. Body composition by bioelectrical impedance predicts mortality in chronic obstructive pulmonary disease patients. Respiratory Medicine 2005; 99 (8): 1004-1009. doi: 10.1016/j.rmed.2004.09.024
31. Ishii S, Tanaka T, Akishita M, Iijima K. Re: Growing research on sarcopenia in Asia. Geriatrics and Gerontology International 2015; 15 (2): 238-239. doi: 10.1111/ggi.12304
32. Tanni SE, Pelegrino NR, Angeleli AY, Correa C, Godoy I. Smoking status and tumor necrosis factor-alpha mediated systemic inflammation in COPD patients. Journal of Inflammation-London 2010; 7: 29. doi: 10.1186/1476-9255-7- 29